Glisen MF Forte 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake and utilization. This dual-action formulation is designed to provide effective glycemic control in patients inadequately managed by diet, exercise, and monotherapy. The prolonged-release (PR) formulation allows for sustained drug release, promoting better patient compliance through reduced dosing frequency and minimizing gastrointestinal side effects commonly associated with Metformin. Glisen MF Forte 2 is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and exercise. It is contraindicated in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. Regular monitoring of blood glucose levels, renal function, and potential adverse effects is essential during therapy. Dose adjustments may be necessary based on therapeutic response and tolerability. This combination therapy offers a synergistic approach to glycemic control, reducing the risk of diabetes-related complications when used appropriately under medical supervision.